

Abstract

The present invention relates to the utilization of a  
10 compound capable of antagonizing at least partially the  
oncogenic activity of the protein Mdm2 for the preparation of a  
pharmaceutical composition intended more particularly to a  
treatment of cancers with no p53 context. It further relates to  
the viral vector comprising a nucleic acid sequence coding for a  
15 compound capable of inhibiting at least partially the oncogenic  
activity of the protein Mdm2, and to a corresponding  
pharmaceutical composition.